Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 8,250 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Humans Clear all
Active, not recruiting Phase 1 Interventional

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

NCT04732845
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
Interventions
Fully human anti CD19 CAR-T Cell Dose, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Benjamin Tomlinson
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 30, 2026, 6:02 PM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.

NCT01224795
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Placebo Comparator
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
96
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Not applicable Interventional

TechMPower: Advancing HIV/SUD Care and Service Delivery for People in Re-entry

NCT07088770
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Substance Abuse Disorder
Interventions
Community Coalition CLS Workgroup/Network of Providers, Tech-mediated Training and Service Delivery, Multidisciplinary Implementation Team with Champion, Tech-mediated Peer Navigation Enhanced Case management (NCM)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kingston, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 30, 2026, 6:02 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

High Resolution Micro OCT Imaging

NCT03256773
View directory record Official record
Conditions
Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis, ILD, Normal Controls
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

NCT04978454
View directory record Official record
Conditions
Influenza
Interventions
Influenza RG-A/Texas/71/2017 (H3N2) Challenge, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 30, 2026, 6:02 PM EDT
Completed No phase listed Observational

Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B

NCT01581554
View directory record Official record
Conditions
Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 6:02 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

NCT00558545
View directory record Official record
Conditions
Human Mammary Carcinoma
Interventions
AEG35156
Drug
Lead sponsor
Aegera Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Phase 2 Interventional

A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy

NCT00000842
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Disease
Interventions
Nerve Growth Factor, Recombinant Human
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
14
States / cities
Los Angeles, California • San Mateo, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 30, 2026, 6:02 PM EDT
Enrolling by invitation No phase listed Observational

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

NCT05768386
View directory record Official record
Conditions
Hemophilia A
Interventions
Not listed
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2040
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 30, 2026, 6:02 PM EDT
Recruiting Phase 1 Interventional

A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer

NCT07481383
View directory record Official record
Conditions
Pancreatic Adenocarcinoma Non-resectable
Interventions
ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003)
Combination Product
Lead sponsor
Continuity Biosciences, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Ann Arbor, Michigan • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Phase 1 Interventional

Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma

NCT00687622
View directory record Official record
Conditions
Solid Tumours
Interventions
GSK1120212
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Scottsdale, Arizona • Aurora, Colorado • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Phase 3 Interventional

Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection

NCT00023153
View directory record Official record
Conditions
HIV Infections, Chronic Hepatitis B
Interventions
Adefovir Dipivoxil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 6:02 PM EDT
Completed No phase listed Observational

Collection of Heart Tissue Sample During Open Heart Surgery

NCT00423553
View directory record Official record
Conditions
Ischemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Phase 1 Interventional

Open-Label Adalimumab for Ulcerative Colitis Patients

NCT00421642
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Phase 2 Interventional

ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

NCT01628094
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
RO5024048, RO5190591, RO5466731, ribavirin [Copegus], ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
La Jolla, California • Englewood, Colorado • South Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of a Novel Product for the Removal of Impacted Human Cerumen (Earwax)

NCT02829294
View directory record Official record
Conditions
Cerumen Impaction of Both Ears
Interventions
E002 - cerumen removal aid
Device
Lead sponsor
Dr. Joseph Griffin
Industry
Eligibility
40 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intake-dependent Effect of Cocoa Flavanol Absorption, Metabolism and Excretion in Humans

NCT03201822
View directory record Official record
Conditions
Healthy
Interventions
100 mg of Cocoa Flavanols/70 kg BW, 200 mg of Cocoa Flavanols/70 kg BW, 400 mg of Cocoa Flavanols/70 kg BW, 1000 mg of Cocoa Flavanols/70 kg BW
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 40 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 30, 2026, 6:02 PM EDT
Terminated Phase 2 Interventional Results available

A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults

NCT04900038
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Dolutegravir, Lamivudine capsules, Lamivudine tablets
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Bakersfield, California • Palm Springs, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Not applicable Interventional

The Human Immunodeficiency Virus and Osteopathic Manipulation Evaluation Study

NCT00703248
View directory record Official record
Conditions
HIV Infections
Interventions
Osteopathic Manipulative Treatments
Procedure
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2008 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

NCT01492426
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Telaprevir, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of TD-0714 in Healthy Subjects

NCT02639078
View directory record Official record
Conditions
Healthy
Interventions
TD-0714, Placebo Comparator
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude

NCT01794078
View directory record Official record
Conditions
Acute Mountain Sickness and Fatigue
Interventions
Aminophylline 400 mg, Ambrisentan 5 mg, Placebo
Drug · Other
Lead sponsor
Robert J Noveck, M.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Oct 30, 2026, 6:02 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06121843
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BMS-986393, Alnuctamab, Mezigdomide, Iberdomide, Elranatamab, Dexamethasone
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 30, 2026, 6:02 PM EDT
Completed Not applicable Interventional

Testing the Use of Prompts to Increase Adolescent Immunization Rates

NCT01984125
View directory record Official record
Conditions
Vaccine Preventable Diseases, Meningococcal Disease, Human Papillomavirus, Pertussis, Influenza
Interventions
Point-of-Care Prompt
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 18 Years
Enrollment
7,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Little Rock, Arkansas • Wilmington, Delaware • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 30, 2026, 6:02 PM EDT